Gavin Giovannoni

Research interests

Publications

• Multiple sclerosis – a review

  European Journal of Neurology · 2018 · https://doi.org/10.1111/ene.13819

• Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)30475-6

• Human Endogenous Retroviruses in Neurological Diseases

  Trends in Molecular Medicine · 2018 · 10.1016/j.molmed.2018.02.007

• Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

  Multiple Sclerosis Journal · 2017 · 10.1177/1352458517727603

• Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

  EBioMedicine · 2017 · 10.1016/j.ebiom.2017.01.042

• Brain health: time matters in multiple sclerosis

  Multiple Sclerosis and Related Disorders · 2016 · 10.1016/j.msard.2016.07.003

• Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

  Multiple Sclerosis Journal · 2015 · 10.1177/1352458514568827

• Neurofilament light chain

  Neurology · 2015 · 10.1212/wnl.0000000000001642

• Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

  Multiple Sclerosis and Related Disorders · 2015 · 10.1016/j.msard.2015.04.006

• Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

  PLoS ONE · 2013 · 10.1371/journal.pone.0075091

• Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude

  Journal of Neurology Neurosurgery & Psychiatry · 2013 · 10.1136/jnnp-2012-304695

• Meta‐analysis of early nonmotor features and risk factors for Parkinson disease

  Annals of Neurology · 2012 · 10.1002/ana.23687

• A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa0902533

• A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution

  Genome Research · 2010 · https://doi.org/10.1101/gr.107920.110

• An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis

  PLoS ONE · 2010 · 10.1371/journal.pone.0012496

• Multiple sclerosis: risk factors, prodromes, and potential causal pathways

  The Lancet Neurology · 2010 · 10.1016/s1474-4422(10)70094-6

• A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

  Neurology · 2009 · https://doi.org/10.1212/wnl.0b013e3181c47cc2

• Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

  Nature Medicine · 2007 · 10.1038/nm1561

• Infectious causes of multiple sclerosis

  The Lancet Neurology · 2006 · 10.1016/s1474-4422(06)70577-4

• Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force

  European Journal of Neurology · 2006 · 10.1111/j.1468-1331.2006.01493.x

• Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.

  PubMed · 2005 · 10.1001/archneur.62.6.865

• The therapeutic potential of cannabis

  The Lancet Neurology · 2003 · 10.1016/s1474-4422(03)00381-8

• Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

  Brain · 2003 · 10.1093/brain/awg224

• The peripheral benzodiazepine binding site in the brain in multiple sclerosis

  Brain · 2000 · 10.1093/brain/123.11.2321

• Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies

  Journal of Neurology Neurosurgery & Psychiatry · 2000 · 10.1136/jnnp.68.4.423

Current projects

No projects listed.